Market Cap 93.32M
Revenue (ttm) 100,000.00
Net Income (ttm) -33.42M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -33,420.00%
Debt to Equity Ratio 0.12
Volume 40,300
Avg Vol 89,392
Day's Range N/A - N/A
Shares Out 47.13M
Stochastic %K 36%
Beta 0.74
Analysts Sell
Price Target $5.83

Company Profile

Adagene Inc., a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers in the People's Republic of China. Its lead product candidate is the ADG126, a masked fully-human anti-CTLA-4 mAb which is in phase 1b/2 clinical development for the treatment of cancer. The company also develops ADG116, a fully human anti-CTLA-4 antibody generated using NEObody technology, which is in phase 1b/2 clinical trials to treat advanced/met...

Industry: Biotechnology
Sector: Healthcare
Phone: 86 512 8777 3632
Address:
Building C14, 4th Floor No. 218, Xinghu Street Suzhou Industrial Park, Suzhou, China
NVDAMillionaire
NVDAMillionaire Oct. 3 at 9:11 AM
$ADAG Excellent article that nails exactly where ADAG stands right now. So if you want to update your ADAG knowledge or get acquainted with ADAG, this is a must read. https://beyondspx.com/quote/ADAG/analysis/adagene-unmasking-precision-in-oncology-immunotherapy-nasdaq-adag
0 · Reply
JarvisFlow
JarvisFlow Sep. 18 at 12:30 PM
LUCID CAPITAL MARKETS has updated their rating for Adagene ( $ADAG ) to Buy with a price target of 9.
0 · Reply
BioTuesdays
BioTuesdays Sep. 16 at 7:08 PM
$ADAG has announced an amendment to the 2021 collaboration and license agreement with Exelixis (Nasdaq: EXEL) to enable the development of a third novel masked monoclonal antibody (mAb) drug conjugate https://biotuesdays.com/2025/09/16/adagene-exelixis-amend-license-agreement-to-develop-third-masked-mab/
0 · Reply
BiotechBagholder
BiotechBagholder Sep. 11 at 7:09 PM
$ADAG Can anyone share the CSCO abstracts and posters?
0 · Reply
kshonstocks
kshonstocks Sep. 9 at 2:25 PM
$ADAG on scans, like chart, taking some
0 · Reply
DARKP00L
DARKP00L Sep. 5 at 2:05 PM
$ADAG 10:02 on Sep. 05 2025 Adagene's Masked CTLA-4 Antibody ADG126 To Be Highlighted In Dual Oral Presentations At 2025 CSCO Meeting; Data Highlights Include Phase 1b/2 Results In MSS CRC And Combination With Pembrolizumab #tradeideas
0 · Reply
BioTuesdays
BioTuesdays Sep. 3 at 2:07 PM
$ADAG has announced the appointment of immuno-oncology pioneer, Axel Hoos, MD, PhD, as executive advisor. https://biotuesdays.com/2025/09/03/adagene-appoints-dr-axel-hoos-as-executive-advisor/
0 · Reply
TheRealShortSqueezy
TheRealShortSqueezy Sep. 2 at 5:06 PM
⏳Medicus Pharma ( $MDCX ) is gaining upward momentum, trading around $2.03 following this morning’s news ⏳ 🤝Today, the company finalized the acquisition of Antev Ltd., adding Teverelix, a next‑generation GnRH antagonist targeting acute urinary retention and high‑CV‑risk prostate cancer—unlocking a $6B+ market opportunity 🎯 This strategic addition bolsters their Phase 2 pipeline and elevates Medicus’s clinical and commercial potential, especially with veteran pharma leader Patrick J. Mahaffy joining the board. 📈Shares are reacting positively—this upward drift suggests growing investor confidence as key catalysts unfold. Levels: 2.09$➡ 2.28$ ➡ 2.46$ ➡ 2.59$ ➡ 2.67$ Website: https://medicuspharma.com Communicated Disclaimer : https://tinyurl.com/2afx6epb Peers: $CRBP $SKYE $ADAG $COYA #Advertisement
2 · Reply
TheRealShortSqueezy
TheRealShortSqueezy Sep. 2 at 1:48 PM
$MDCX On the verge of a breakout after that game-changing news hit this morning. 🚀2.05$ breakout is key !! 🚨 Medicus Pharma ($MDCX) has officially closed the acquisition of Antev Ltd., bringing in Teverelix — a next-gen GnRH antagonist with blockbuster potential. Teverelix is positioned as a first-in-class treatment for acute urinary retention (AURr) and a best-in-class option for advanced prostate cancer patients with high cardiovascular risk. Together, these indications represent a $6B+ market opportunity. Adding to the excitement, veteran pharma executive Patrick J. Mahaffy (ex-Clovis, ex-Pharmion) has joined the board, strengthening leadership as $MDCX advances multiple Phase 2b trials. This deal supercharges Medicus’s pipeline and sets the stage for major near-term catalysts. 🚀📈 Website: https://medicuspharma.com Communicated Disclaimer : https://tinyurl.com/2afx6epb Peers: $CRBP $SKYE $ADAG $COYA
1 · Reply
TheRealShortSqueezy
TheRealShortSqueezy Sep. 2 at 11:59 AM
🚨👇🏽Bottomed low float BIO ready to reverse 👇🏽🚨 ➡➡ Medicus Pharma Ltd ( Nasdaq : $MDCX ) ⬅⬅ Medicus Pharma is a biotech advancing disruptive therapies through partnerships, acquisitions, and in-house programs. Key Catalysts Ahead: 1️⃣Phase II SKNJCT-003: Interim data shows 60%+ lesion clearance with the D-MNA patch; trial expanded to 90 patients across U.S. & EU sites. 2️⃣FDA Type C Meeting (Q4 2025): Potential fast-track path toward NDA filing. 3️⃣Antev Acquisition: Adds Teverelix, targeting the $15B prostate cancer market. 4️⃣Veterinary Oncology: FDA MUMS designation opens a $250M+ equine cancer market with little competition. 📈The chart is forming a strong multi-bottom base on the daily. A breakout above $2.10 could trigger a momentum shift to the upside. Website: https://medicuspharma.com/ Communicated Disclaimer : https://tinyurl.com/2afx6epb Peers: $CRBP $SKYE $ADAG $COYA
0 · Reply
Latest News on ADAG
Adagene to Participate in Two Investor Conferences in September

Aug 26, 2025, 8:05 AM EDT - 5 weeks ago

Adagene to Participate in Two Investor Conferences in September


Adagene Appoints John Maraganore, Ph.D. as Executive Advisor

Apr 28, 2025, 8:00 AM EDT - 5 months ago

Adagene Appoints John Maraganore, Ph.D. as Executive Advisor


Adagene to Present at 11th Annual Immuno-Oncology 360⁰ Summit

Mar 13, 2025, 8:00 AM EDT - 7 months ago

Adagene to Present at 11th Annual Immuno-Oncology 360⁰ Summit


Adagene to Present at Investor Conferences in June

May 22, 2024, 4:45 PM EDT - 1 year ago

Adagene to Present at Investor Conferences in June


Adagene Announces Updates to its Board of Directors

Apr 28, 2023, 7:00 AM EDT - 2 years ago

Adagene Announces Updates to its Board of Directors


Adagene to Participate in Investor Conferences in May and June

May 12, 2022, 7:00 AM EDT - 3 years ago

Adagene to Participate in Investor Conferences in May and June


NVDAMillionaire
NVDAMillionaire Oct. 3 at 9:11 AM
$ADAG Excellent article that nails exactly where ADAG stands right now. So if you want to update your ADAG knowledge or get acquainted with ADAG, this is a must read. https://beyondspx.com/quote/ADAG/analysis/adagene-unmasking-precision-in-oncology-immunotherapy-nasdaq-adag
0 · Reply
JarvisFlow
JarvisFlow Sep. 18 at 12:30 PM
LUCID CAPITAL MARKETS has updated their rating for Adagene ( $ADAG ) to Buy with a price target of 9.
0 · Reply
BioTuesdays
BioTuesdays Sep. 16 at 7:08 PM
$ADAG has announced an amendment to the 2021 collaboration and license agreement with Exelixis (Nasdaq: EXEL) to enable the development of a third novel masked monoclonal antibody (mAb) drug conjugate https://biotuesdays.com/2025/09/16/adagene-exelixis-amend-license-agreement-to-develop-third-masked-mab/
0 · Reply
BiotechBagholder
BiotechBagholder Sep. 11 at 7:09 PM
$ADAG Can anyone share the CSCO abstracts and posters?
0 · Reply
kshonstocks
kshonstocks Sep. 9 at 2:25 PM
$ADAG on scans, like chart, taking some
0 · Reply
DARKP00L
DARKP00L Sep. 5 at 2:05 PM
$ADAG 10:02 on Sep. 05 2025 Adagene's Masked CTLA-4 Antibody ADG126 To Be Highlighted In Dual Oral Presentations At 2025 CSCO Meeting; Data Highlights Include Phase 1b/2 Results In MSS CRC And Combination With Pembrolizumab #tradeideas
0 · Reply
BioTuesdays
BioTuesdays Sep. 3 at 2:07 PM
$ADAG has announced the appointment of immuno-oncology pioneer, Axel Hoos, MD, PhD, as executive advisor. https://biotuesdays.com/2025/09/03/adagene-appoints-dr-axel-hoos-as-executive-advisor/
0 · Reply
TheRealShortSqueezy
TheRealShortSqueezy Sep. 2 at 5:06 PM
⏳Medicus Pharma ( $MDCX ) is gaining upward momentum, trading around $2.03 following this morning’s news ⏳ 🤝Today, the company finalized the acquisition of Antev Ltd., adding Teverelix, a next‑generation GnRH antagonist targeting acute urinary retention and high‑CV‑risk prostate cancer—unlocking a $6B+ market opportunity 🎯 This strategic addition bolsters their Phase 2 pipeline and elevates Medicus’s clinical and commercial potential, especially with veteran pharma leader Patrick J. Mahaffy joining the board. 📈Shares are reacting positively—this upward drift suggests growing investor confidence as key catalysts unfold. Levels: 2.09$➡ 2.28$ ➡ 2.46$ ➡ 2.59$ ➡ 2.67$ Website: https://medicuspharma.com Communicated Disclaimer : https://tinyurl.com/2afx6epb Peers: $CRBP $SKYE $ADAG $COYA #Advertisement
2 · Reply
TheRealShortSqueezy
TheRealShortSqueezy Sep. 2 at 1:48 PM
$MDCX On the verge of a breakout after that game-changing news hit this morning. 🚀2.05$ breakout is key !! 🚨 Medicus Pharma ($MDCX) has officially closed the acquisition of Antev Ltd., bringing in Teverelix — a next-gen GnRH antagonist with blockbuster potential. Teverelix is positioned as a first-in-class treatment for acute urinary retention (AURr) and a best-in-class option for advanced prostate cancer patients with high cardiovascular risk. Together, these indications represent a $6B+ market opportunity. Adding to the excitement, veteran pharma executive Patrick J. Mahaffy (ex-Clovis, ex-Pharmion) has joined the board, strengthening leadership as $MDCX advances multiple Phase 2b trials. This deal supercharges Medicus’s pipeline and sets the stage for major near-term catalysts. 🚀📈 Website: https://medicuspharma.com Communicated Disclaimer : https://tinyurl.com/2afx6epb Peers: $CRBP $SKYE $ADAG $COYA
1 · Reply
TheRealShortSqueezy
TheRealShortSqueezy Sep. 2 at 11:59 AM
🚨👇🏽Bottomed low float BIO ready to reverse 👇🏽🚨 ➡➡ Medicus Pharma Ltd ( Nasdaq : $MDCX ) ⬅⬅ Medicus Pharma is a biotech advancing disruptive therapies through partnerships, acquisitions, and in-house programs. Key Catalysts Ahead: 1️⃣Phase II SKNJCT-003: Interim data shows 60%+ lesion clearance with the D-MNA patch; trial expanded to 90 patients across U.S. & EU sites. 2️⃣FDA Type C Meeting (Q4 2025): Potential fast-track path toward NDA filing. 3️⃣Antev Acquisition: Adds Teverelix, targeting the $15B prostate cancer market. 4️⃣Veterinary Oncology: FDA MUMS designation opens a $250M+ equine cancer market with little competition. 📈The chart is forming a strong multi-bottom base on the daily. A breakout above $2.10 could trigger a momentum shift to the upside. Website: https://medicuspharma.com/ Communicated Disclaimer : https://tinyurl.com/2afx6epb Peers: $CRBP $SKYE $ADAG $COYA
0 · Reply
shawky1
shawky1 Aug. 28 at 2:19 PM
0 · Reply
shawky1
shawky1 Aug. 28 at 12:11 PM
$ADAG +2.50
0 · Reply
_www_larval_com_
_www_larval_com_ Aug. 15 at 7:57 PM
$CUPR 10%[-87%] $CASI -8%[23%] $MAGH -7%[-62%] $TIVC -6%[1%] $ADAG -5%[-15%] most notable movement into the final minutes of trading.
0 · Reply
JarvisFlow
JarvisFlow Aug. 15 at 11:30 AM
HC Wainwright & Co. has adjusted their stance on Adagene ( $ADAG ), setting the rating to Buy with a target price of 8 → 7.
0 · Reply
Thestocktraderhubzee
Thestocktraderhubzee Aug. 13 at 2:42 PM
$ADAG Adagene shares are trading higher after the company reported better-than-expected H1 adjusted EPS results.
0 · Reply
builderup
builderup Aug. 8 at 2:40 PM
Research, Buy, Hold and Profit! What a difference a couple of weeks make. $BTAI $ADAG - just getting started……
0 · Reply
SadyK189
SadyK189 Aug. 7 at 1:17 AM
Top Stocks to watch tomorrow 1 / 2: $GNS $HLLY $COSM $ADAG $AIMD GNS: Getting up on 4hours chart. 0.91 - 0.95 is acting as key support zone. Next key level to test is 1.42 - 1.53. Currently at 1.19 HLLY: Good close of daily candle. Key support at 1.95 - 2.15. Next key level to test is 3.35 - 3.60. Currently at 2.75 COSM is trending nicely on daily chart from sometime now. 0.83 - 0.88 is acting as key support zone. Next key level to test is 1.38 - 1.50. Currently at 1.12. It may take sometime though. ADAG: Good close of daily candle. Key support at 1.65 - 1.80. Next key level to test 2.85 - 3.10. Currently at 2.34. AIMD: After making a nice run, AIMD fell to its key support zone of 3.1 - 3.35. It may get a bounce off this support zone to 4+ again. Currently at 3.35
0 · Reply
JarvisFlow
JarvisFlow Aug. 6 at 12:30 PM
Leerink Partners has adjusted their stance on Adagene ( $ADAG ), setting the rating to Outperform with a target price of 7.
0 · Reply
mru01
mru01 Jul. 15 at 2:51 PM
$ADAG don't understand why this is dropping after that good news. Any comments?
1 · Reply
StocktwitsNews
StocktwitsNews Jul. 15 at 1:20 PM
Adagene Receives FDA Guidance On Future Clinical Development Of Experimental Cancer Drug: Retail Turns Optimistic $ADAG $MRK https://stocktwits.com/news/equity/markets/adagene-receives-fda-guidance-on-future-clinical-development-of-experimental-cancer-drug/ch8QdxaR5FS
0 · Reply
AC33
AC33 Jul. 15 at 11:48 AM
$ADAG on watch for today
0 · Reply
Thestocktraderhubzee
Thestocktraderhubzee Jul. 8 at 11:04 AM
$ADAG Adagene Partners With ConjugateBio To Advance Bispecific Antibody Drug Conjugates Using Proprietary Antibody
0 · Reply